Insulet, NewAmsterdam, Protagonist, and Biomea Q2 ’26 Earnings; Vivani Completes Initial Dosing for Sema Implant; CVS Expands GLP-1RA Support
A series of cardiometabolic-related news items has been observed from Insulet, NewAmsterdam Pharma, Protagonist Therapeutics, Biomea Fusion, Vivani Medical, and CVS Health. Below, FENIX provides highlights and insights for the respective news items.
This content is for Read Less members only.
Already a member? Log in here